Rhea J. Posedel, a director at Aehr Test Systems, sold 15,000 shares of the company's stock on April 16, 2026, for a total of $1.21 million. This transaction took place as the stock trades near $80.85, following a remarkable 891% gain over the past year. Despite this surge, analysts suggest the stock is overvalued due to high revenue valuation multiples and profitability challenges. Aehr Test Systems recently announced a record $41 million production order for the package-level testing of custom AI processor ASICs, which is expected to begin in fiscal 2027. In its latest financial report for Q3 2026, the company reported an earnings per share of -$0.05, which was better than the expected -$0.07, but revenue fell short at $10.3 million, compared to the forecast of $10.8 million. Nevertheless, Aehr achieved record quarterly bookings of $37.2 million, resulting in a backlog exceeding $50 million. Following these developments, analysts have increased their price targets for the stock, with Freedom Broker raising it to $61 from $38 and Lake Street increasing it to $56 from $50.